Harrow Health is trading $38.38 (-5.69%) after its August 10 earnings release showed a wider-than-expected adjusted loss of $0.46 per share and revenue of $70.7 million below estimates. - VEVYE revenue rose 40% sequentially. - The company reaffirmed 2026 guidance of $350–$365 million in revenue and $80–$100 million adjusted EBITDA. - No reliable volume data was provided.